16 completed. 16 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 16 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Favipiravir vs Hydroxychloroquine vs Control in COVID -19 Hydroxychloroquine, Favipiravir, Routine care for COVID-19 patients - SARS-CoV 2, COVID-19 | Phase 2 | Completed | Royal College of Surgeons in Ireland - Medical University of Bahrain | 150 | 2020-08-11 | 2021-10-26 |
| Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer - Coronavirus Infection, SARS-CoV 2 | Phase 1 / Phase 2 | Completed | International Vaccine Institute | 79 | 2020-07-15 | 2022-07-18 |
| Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19 Melatonin intravenous, Placebo intravenous - COVID-19, SARS-CoV 2 | Phase 2 | Completed | Pharmamel S.L. | 18 | 2020-06-20 | 2021-03-18 |
| The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) EIDD-2801, Placebo - SARS-CoV 2 | Phase 2 | Completed | Ridgeback Biotherapeutics, LP | 71 | 2020-06-16 | 2023-03-23 |
| Convalescent Plasma to Limit SARS-CoV-2 Associated Complications SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor - SARS-CoV 2 | Phase 2 | Completed | Johns Hopkins University | 1225 | 2020-06-03 | 2023-06-02 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebo - COVID 19, SARS-CoV 2 | Phase 2 | Completed | Kristin Hudock | 1 | 2020-05-20 | 2024-12-09 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebos - COVID 19, SARS-CoV 2 | Phase 2 | Completed | The Cleveland Clinic | 40 | 2020-05-20 | 2021-05-13 |
| Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 XCEL-UMC-BETA, Placebo - COVID-19, SARS-CoV 2 | Phase 1 / Phase 2 | Completed | Banc de Sang i Teixits | 26 | 2020-05-13 | 2023-01-26 |
| A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 ArtemiC, Placebo - COVID-19, Corona Virus Infection | Phase 2 | Completed | MGC Pharmaceuticals d.o.o | 50 | 2020-05-08 | 2021-08-31 |
| Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome BAT + Calcifediol, BAT - SARS-CoV 2, COVID19 | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 517 | 2020-05-07 | 2023-03-03 |
| Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma - Corona Virus Infection, SARS-CoV 2 | Phase 2 | Completed | University of Virginia | 29 | 2020-05-05 | 2022-04-01 |
| COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients Povidone-Iodine Nasal Spray and Gargle - COVID-19, SARS-CoV 2 | Phase 2 | Completed | Nikita Gupta | 98 | 2020-04-29 | 2022-12-02 |
| Clinical Trial of Sarilumab in Adults With COVID-19 Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA], Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA], Best available treatment - SARS-CoV 2, SARS | Phase 2 | Completed | Maimónides Biomedical Research Institute of Córdoba | 120 | 2020-04-28 | 2021-07-07 |
| Canakinumab in Covid-19 Cardiac Injury (The Three C Study) Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos - COVID-19, SARS-CoV 2 | Phase 2 | Completed | The Cleveland Clinic | 45 | 2020-04-24 | 2021-04-15 |
| Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection Hyperimmune plasma, Standard of care for SARS-CoV-2 infection - SARS-CoV 2 | Phase 1 / Phase 2 | Completed | Andalusian Network for Design and Translation of Advanced Therapies | 72 | 2020-04-23 | 2022-04-06 |
| Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers. Melatonin 2mg, Placebo oral tablet - Covid19, SARS-CoV 2 | Phase 2 / Phase 3 | Completed | Instituto de Investigación Hospital Universitario La Paz | 450 | 2020-04-20 | 2021-11-23 |
COVID-19 (11) · Coronavirus Infections (5) · Pneumonia (3) · Cytokine Release Syndrome (1) · Respiratory Distress Syndrome (1) · Severe Acute Respiratory Syndrome (1)
Coronaviridae Infections (13) · Infections (13) · Nidovirales Infections (13) · RNA Virus Infections (13) · Virus Diseases (13) · Lung Diseases (12) · Respiratory Tract Diseases (12) · Respiratory Tract Infections (12) · Pneumonia, Viral (11) · Pneumonia (9) · Coronavirus Infections (8) · Inflammation (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiration Disorders (1)
COVID-19 Serotherapy (2) · mavrilimumab (2) · Buffers (1) · Calcifediol (1) · Hydroxychloroquine (1) · Melatonin (1) · Mouthwashes (1) · Standard of Care (1) · canakinumab (1) · favipiravir (1) · glycine N-choloyltransferase (1) · molnupiravir (1) · reluscovtogene ralaplasmid (1) · sarilumab (1)
Maimónides Biomedical Research Institute of Córdoba (2) · The Cleveland Clinic (2) · Andalusian Network for Design and Translation of Advanced Therapies (1) · Banc de Sang i Teixits (1) · Instituto de Investigación Hospital Universitario La Paz (1) · International Vaccine Institute (1) · Johns Hopkins University (1) · Kristin Hudock (1) · MGC Pharmaceuticals d.o.o (1) · Nikita Gupta (1) · Pharmamel S.L. (1) · Ridgeback Biotherapeutics, LP (1) · Royal College of Surgeons in Ireland - Medical University of Bahrain (1) · University of Virginia (1)
United States (7) · Spain (6) · Bahrain (1) · India (1) · Israel (1) · South Korea (1)
Paul C Cremer, M. D. (2) · Alberto M Borobia, MD, PhD (1) · Alexandra E Kejner, MD (1) · Antoni Torres, MD, PhD (1) · Antonio J Carcas (1) · Ashwin Balagopal, MD (1) · David J Sullivan, MD (1) · Eu Suk Kim, MD (1) · Kristin Hudock, MD (1)
PMID 33754144, PMID 32936949, PMID 33191263, PMID 33273742, PMID 34029377, PMID 34902262, PMID 34981068, PMID 35322077, PMID 35353960, PMID 36722044, PMID 37131659, PMID 38483534
R01AI152078 (1), U24TR001609 (1), UL1TR003098 (1)